31 Mar 20
tranScrip is pleased to note that Synairgen has confirmed commencement of first patient dosing in a trial of SNG001 in COVID-19.
tranScrip continues to support Synairgen in this important endeavour, a continuation of being at the heart of the development of SNG001 (inhaled formulation of interferon-beta-1a) for the last 12 years.
Get in touch to see how our senior cross-functional experts can help you reduce risk, protect value, and move forward with confidence.
